BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leads

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
282
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team

- The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb
- The team has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza candidate, and built, owns, and operates its GMP biologics manufacturing facility
- BiondVax has an exclusive collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), to develop a pipeline of innovative nanosized antibody therapies
- BiondVax’s experience, assets, and pipeline represent a rare opportunity for a company of its size

BiondVax Pharmaceuticals (NASDAQ: BVXV), a Jerusalem-based biotechnology company, is laser focused on developing, manufacturing, and commercializing innovative NanoAb immunotherapeutic products, primarily for treating infectious and autoimmune diseases. Collaborating with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen (“UMG”), both in Germany, BiondVax is developing a pipeline of nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as nanobodies and VHH-antibodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production.

BiondVax’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis (NYSE: NVS), GSK (NYSE: GSK), and Bristol-Myers Squibb (NYSE: BMY). This team plays a vital role in the company’s pursuit to advance nanosized antibody innovation from R&D through commercialization and includes:

Mr. Amir Reichman, CEO of BiondVax, was most recently the Head of Global Vaccines Engineering Core Technologies and Asset Management at GSK Vaccines in Belgium. Mr. Reichman earned his M.Sc. in Biotechnology Engineering from the Ben-Gurion University of the Negev in Israel and an MBA in Finance and Health Care Management from the Wharton School of the University of Pennsylvania, USA.

Dr. Tamar Ben-Yedidia, Ph.D., CSO of BiondVax, has more than 30 years of experience in the field of immunology, with expertise in the development of vaccines. She started her career with Biotechnology General Ltd, BTG (Rehovot), working on developing a recombinant Hepatitis-B vaccine. Dr. Ben-Yedidia received her Ph.D. from the Weizmann Institute after completing her doctoral thesis entitled “A Peptide-Based Vaccine Against Influenza” in the lab of Professor Ruth Arnon, co-inventor of the blockbuster multiple sclerosis drug Copaxone®

Mr. Elad Mark, COO of BiondVax, is an executive leader with over 15 years of biotechnology industry experience encompassing diverse project stages, including feasibility studies, conceptual and detailed design, commissioning qualification, and process validation. Mr. Mark holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Mr. Uri Ben-Or, CFO of BiondVax, has over 25 years of experience in corporate finance, accounting, M&A transactions, and IPOs. His experience also includes serving as CFO in public life science companies traded on the TASE, OTC, and NASDAQ exchanges. Mr. Ben-Or holds a B.A. in Business, an MBA from Bar-Ilan University, and is a Certified Public Accountant.

Dr. Dalit Weinstein Fischer, Ph.D., is BiondVax’s Head of Technical R&D. She is the previous Director of Biological Processes at NanoSpun Technologies Ltd. and CTO at VAYU Sense AG, specializing in improving bio-based fermentation processes with an AI-based controller. Dr. Weinstein Fischer holds a Ph.D. from the Hadassah Medical School, Molecular Genetics and Microbiology Department, Hebrew University of Jerusalem.

Mrs. Moran Ahdout Fruchter is the Chief of Staff for BiondVax and brings over ten years of broad legal and international transactional experience. Before joining BiondVax, she served as General Counsel at Miya Group, overseeing legal affairs of the group worldwide, led negotiations, was involved in global growth activities and M&A transactions, and provided legal guidance to senior management and the board. Mrs. Ahdout Fruchter holds an LL.B. in Law and a B.A. in Economics from Tel Aviv University and is admitted to the Israel Bar Association.

Ms. Merav Kamensky is the Senior Manager of Quality Control for BiondVax. Her experience includes laboratory research from the University of Waterloo, Canada, and in the biopharmaceutical industry, including positions at Abic Biological Laboratories Teva Ltd and InSight Biopharmaceuticals Ltd. Ms. Kamensky earned a BSc. and MSc. in Biotechnology and Agriculture from The Hebrew University of Jerusalem.

Mr. Joshua E. Phillipson is the Director of Communications and Investor Relations, leading BiondVax’s business development and communications activities, including marketing, investor, and public relations since 2015. Mr. Phillipson earned an Honours BSc. from the University of Toronto and an MBA from the Ben-Gurion University of the Negev.

Since the company’s foundation, it has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza candidate. It built, owns, and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities, and offices, through which BiondVax drives NanoAb therapeutics development and innovation. To optimize operational efficiency, BiondVax also offers its assets to companies through its CDMO services in Israel.

The combination of BiondVax’s experience, assets, and developing pipeline are rare for a company of its size, positioning it well for a promising future.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links

BVXV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 91

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 88

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 103

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 50

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 111

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Weight Loss Solutions: ASC36 and ASC35 Development

Updated Category News Views 312

Exciting Co-formulation Advancements by Ascletis Pharma Ascletis Pharma Inc. has made a significant stride in obesity treatment with the co-formulation of ASC36, a monthly amylin receptor agonist, and ASC35, a GLP-1R/GIPR dual agonist. These innovative therapies aim to offer better patient outcomes through advanced pharmacokinetic profiles and a robust efficacy in weight...

Continue Reading
Schouw & Co. Reports Steady Q1 Performance Amidst Challenges

Updated Category News Views 291

Overview of Q1 2025 Performance Recently, Schouw & Co. disclosed their interim report for the first quarter of 2025, highlighting a performance that generally met expectations despite ongoing economic turbulence. While the disturbances in the market have generated caution among customers, the direct effects on Schouw & Co.'s operations seem to have been minimal. Key...

Continue Reading
Parker Hannifin to Present at Jefferies Industrials Conference

Updated Category News Views 153

Parker Hannifin Set to Present at the Jefferies Industrials Conference Parker Hannifin Corporation (NYSE: PH), a recognized leader in motion and control technologies worldwide, has announced its participation in the prestigious Jefferies Industrials Conference. This important event will take place in early September, bringing together industry leaders and innovators to...

Continue Reading
374Water Innovatively Enhances Waste Management Solutions

Updated Category News Views 121

Revolutionizing Waste Management with AirSCWO Technology DURHAM, N.C. – 374Water Inc. (NASDAQ: SCWO) is making significant advancements with its innovative AirSCWO technology aimed at revolutionizing waste management practices. The Company has partnered with the Orange County Sanitation District (OC San) to implement its cutting-edge AirSCWO 6 System at their treatment...

Continue Reading
SharpLink Gaming Expands Footprint in Crypto Gaming Market

Updated Category News Views 548

SharpLink Gaming Advances in Crypto Gaming with Strategic Investment SharpLink Gaming, Inc. (NASDAQ: SBET), a notable player in online marketing for sports betting and iGaming, has declared an exciting venture that marks its entry into the rapidly growing crypto gaming sector. Recently, the company secured a 10% equity stake in Armchair Enterprises, the parent company of...

Continue Reading